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STEM CELL DEVELOPMENT AND THE PATHWAY MODEL:
SCIENTIFIC PUZZLES AND BIOETHICAL ISSUES
Lauren N. Ross, M.A., Ph.D.
University of Pittsburgh, 2016
This thesis examines various scientific puzzles and bioethical issues that are related to the
pathway model of stem cell development. This model has been criticized in the bioethics and
philosophy of science literature by those who claim that it: (1) oversimplifies development in
ways that misrepresent scientific understanding,1 (2) leads to poorly informed scientific and
clinical decision-making,2 and (3) lacks appropriate justification.3 Robert et al (2006) rely on
these points to claim that scientists who rely on this model are acting “unethically,” because
the model inaccurately oversimplifies development and suggests unrealistic future therapies.4
In this project I provide an analysis of the rationale that underlies the pathway model in
the context of hematopoietic stem cell biology. I suggest that this model is representative
of current scientific understanding and that it can be used to appropriately inform decision-
making. In order for this model to appropriately figure in various decision-making processes,
the assumptions and reasoning strategies that it depends on must be appreciated, as these
clarify the scope and limits of the model.
1(Robert, 2004).
2(Robert, Maienschein, and Laubichler, 2006).
3(Oyama, 1998; Oyama, Griffiths, and Gray, 2001).
4[23](Robert et al., 2006).
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1.0 INTRODUCTION
In the bioethics and philosophy of science literature, the claim that biological phenomena
are causally complex has become somewhat of a truism. For any biological phenomenon of
interest, there often seem to be a multitude of causal factors that work together to produce
it. However, when scientists explain and discuss biological outcomes, they do not always cite
or appeal to a large amounts of causal detail and they seem to simplify characterizations
of the causes at work. One example of such a simplification, is the pathway model of
stem cell development–a model that represents a linear sequence of developmental steps,
where few causal factors are represented as controlling each of these steps.12 Recently, this
model has come under attack in both the bioethics and philosophy of science literature,
which claim that it: oversimplifies the developmental process in ways that misrepresent our
best scientific understanding (Robert, 2004), leads to poorly informed scientific and clinical
decision-making (Robert et al., 2006), and lacks appropriate justification (Oyama, 1998;
Oyama et al., 2001). The attention that this model draws in stem cell biology and the
public sphere warrants taking a closer look at these criticisms. What is our best scientific
understanding of stem cell development and how does this model capture, or fail to capture,
this work? What rationale, if any, underlies the ways that this model simplifies the causal
complexity of development? Finally, how should this model influence decision-making in
1Discussion of stem cells in the bioethics literature has typically focused on ethical issues related to
their extraction and grown from human embryos (Shapiro, 1999; McLaren, 2001; Lo and Parham, 2009). As
recent developments have allowed scientists to cultivate pluripotent stem cells without using human embryos–
cells referred to as induced pluripotent stem cells–it has been argued that many ethical debates focused on
human embryos are or will become outdated (Hurlbut and Robert, 2012). In either case, this paper focuses
on another topic related to stem cells and stem cell development, viz. the simplification complex processes
like development and how these relate to bioethical issues.
2An example of this model, from the context of hematopoietic stem cell biology, is displayed in Figure 1
of chapter 2.
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various contexts like medical research and clinical practice?
This project examines the rationale behind the pathway model of stem cell development
and it explores how this model should influence decision-making. My analysis in this thesis
focuses on hematopoietic stem cells, which give rise to the cellular components of the blood.
This cell type provides a useful example to analyze, because hematopoietic stem cells are
viewed as “a paradigm” for understanding adult mammalian stem cell biology,3 they have
influenced the creation of “basic concepts” in stem cell biology,4 and they are the most
well-understood stem cell system.5
The rest of this thesis is outlined as follows. In the second chapter, I examine criticisms
of this model in more detail, in particular, criticisms from the perspectives of bioethics and
philosophy of science. A significant portion of this chapter is devoted to providing a positive
analysis of the reasoning behind the content and use of this model. This analysis relies on
Woodward’s (2003) interventionist account of causation and further distinctions I suggest
among types of causal factors. I argue that the simplifications inherent to this model are
justified by a principled and appropriate rationale, but that these simplifications depend on
assumptions that should be make explicit when the model is used to explain development.
The third chapter of this thesis examines how the pathway model of hematopoietic stem cell
development should figure in medical decision-making. This chapter focuses on clarifying
the limits and scope of this model. I examine three main features that constrain the use of
this model in decision-making. These constraints include (1) the type of stem cells under
consideration, (2) the surrounding environment of the stem cells, and the (3) form of stem
cell treatment being discussed.
This thesis explores a connection between distinct projects that have taken place in
the domains of bioethics and philosophy of science. My work is motivated by the view
that ethical considerations associated with the pathway model are helpfully informed by an
understanding of the scientific reasoning that supports the model. An additional motivation
is that for whatever methods and strategies are employed in scientific contexts, reflection
3 (Li and Li, 2006) (Orkin and Zon, 2008, 641), (Ema, Kobayashi, and Nakauchi, 2010, 2).
4(Ema et al., 2010, 2).
5(Blank, Karlsson, and Karlsson, 2008, 492),(Orkin and Zon, 2008, 641),(Rosenbauer and Goodell, 2014,
65).
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on associated ethical issues is valuable and provides an important larger picture view of
scientific practice. In short, there are good reasons to view connections between bioethics
and philosophy of science as important and worth exploring.
3
2.0 PATHWAY MODEL: RATIONALE
2.1 INTRODUCTION
In the bioethics and philosophy of science literature an increasingly common claim is that
scientists over-simplify complex biological phenomena in problematic ways. These claims
have targeted discussions of development1 and the monocausal model of disease,2 which both
appear to privilege very few causal factors, while leaving many other causes unaccounted for.
In these cases, it has been claimed that scientists simplify biological phenomena in ways that:
(a) misrepresent our best scientific theories and understanding,3 (b) lead to poorly informed
scientific and clinical decision-making,4 and (c) lack appropriate justification.5 More recently,
these claims have been extended to the particular context of stem cell biology, where concise
linear pathways are used to represent stem cell development, which is the process by which
stem cells differentiate into various cell types. In this chapter I focus on these pathway
models6 of stem cell development, the criticisms they have faced in the literature, and what
reasoning, if any, underlies their use in stem cell biology.
An example of one of these pathway diagrams is shown in Figure 1, which represents
the differentiation (or development) of hematopoietic stem cells.7 Hematopoiesis refers to
the development of a particular precursor stem cell (a multipotent hematopoietic stem cell)
into various cellular components of the blood (e.g. erythrocytes, lymphocytes, monocytes,
1(Oyama, 1998, 2000).
2(Alex Broadbent, 2009; Griffiths, 2006; Kitcher, 2003; Kendler, 2012).
3(Robert, 2004).
4(Robert et al., 2006).
5(Oyama, 1998, 2000; Oyama et al., 2001).
6This type of model is also called models are also called a “ ‘classical’ hierarchy diagram ”(Orkin and
Zon, 2008, 641).
7I will discuss hematopoiesis and this pathway diagram in more detail later on in the paper.
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platelets, and granulocytes). In this model an early precursor stem cell is located upstream,
while the variety of cell types that the precursor can form are located downstream.8 The cell
types are connected by arrows, where factors that control or support each step are represented
along each arrow. This type of pathway model is the focus of recent criticisms in the bioethics
literature. Robert et al (2006) support the claim that these pathway characterizations are
merely a “tongue-in-cheek” model, which scientists do not support or fully endorse.9 These
authors claim that scientists who use this model “are behaving unethically, because this
particular way of simplifying the science suggests promises for therapeutic applications that
we know to be extremely improbable” (23). Finally, Robert et al (2006) maintain that the
pathway model “badly informs scientific and clinical decision making” (21). They suggest
that one reason for this, is that the model incorrectly suggests that particular factors control
or drive development, in the way that we might simply drive a car along a road. The authors
view this model as overly simplified in the sense that it (1) only cites a subset of all of the
causes involved in development and (2) naively suggests that these few factors have “control”
over the development process. The authors suggest that a more realistic and scientifically
grounded understanding of development supports a “holistic” and “dynamic” view of this
process, where many causal factors interact in complex ways to orchestrate a developmental
process. This dynamic process is not amenable to the identification of few causal factors
with control over development, as the pathway model suggests.
These criticisms of the pathway model in stem cell biology lead to a number of puzzles.
If this model is a gross misrepresentation of our best scientific understanding of stem cell
biology, why do scientists in this field continue to use it? If this is merely a tongue-and-cheek
model, why do scientists seem to suggest that this model is both accurate and valuable? In
this chapter I argue that there are principled and justified reasons for employing pathway
characterizations in explanations of stem cell development. However, I will suggest that
these characterizations rely on particular assumptions and goals that need to be appreciated
in order to understand the limits and scope of such characterizations, and how they should
inform decision-making. In this chapter I focus on providing an analysis of the rationale
8In Figure 1 the upstream cells are located at the top of the page, while the downstream cells are located
at the bottom of the page.
9(Robert et al., 2006, 21).
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that underlies the pathway model, while in the following chapter I further examine how the
assumptions, scope, and limitations of this model clarify how it should be used in decision-
making. My analysis in these chapters will focus on a particular type or lineage of stem
cells, which are referred to as hematopoetic stem cells (HSC). This cell type provides a useful
example, because they are viewed as “as paradigm” for understanding adult mammalian stem
cell biology,10 they have influenced the creation of “basic concepts” in stem cell biology,11
they are the most well-understood stem cell system,12 and they are “the only stem cells
routinely used in the clinic.”13
2.2 THE PATHWAY MODEL OF STEM CELL DEVELOPMENT:
The pathway concept is very common in biology and biomedicine. Scientists discuss metabolic
pathways, cell-signaling pathways, gene expression pathways, developmental pathways, and
pathways from genotype to phenotype.14 The use of this concept in stem cell biology has
similarities to its use in these other biological contexts. I will mention some of these similar-
ities throughout my analysis, insofar as they help clarify the reasoning behind this concept
in stem cell biology. In the following section, I will suggest that the pathway model involves
at least three main features: (1) a sequence of ordered steps, (2) where some phenomenon
or trait is represented at each step, and (3) where these steps are caused by controlling or
regulatory factors. After clarifying these features, the rest of my analysis will focus on the
three main questions: What are the main features that characterize the pathway model in
stem cell biology? How do scientists rely on this concept in their explanations of develop-
ment? In particular, if development is a causally complex process how and why do pathway
models contain such sparse causal detail?
A significant focus of stem cell biology is on the development or differentiation15 of stem
10 (Li and Li, 2006) (Orkin and Zon, 2008, 641), (Ema et al., 2010, 2).
11(Ema et al., 2010, 2).
12(Blank et al., 2008, 492),(Orkin and Zon, 2008, 641),(Rosenbauer and Goodell, 2014, 65)
13(Rosenbauer and Goodell, 2014, 65).
14For further discussion of the pathway concept in biology, see (Schaffner, 2008).
15I use these terms interchangeable, following the scientific literature.
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cells. While scientists are interested in understanding and explaining many features of stem
cells (e.g., their ability to self-renew), it is their capacity for differentiation that motivates
the use of the pathway model. Differentiation in this context, refers to a set of changes in
the state or phenotype of a biological system over time. These changes are understood as
taking place in a sequential fashion, where one state precedes a second state, the second state
precedes a third state, and so on. The sequential nature of these changes is one important
motivation for the pathway model—a path or sequence of steps is used to represent the
ordered changes that stem cells undergo. With respect to the pathway model for stem cell
development, the sequential steps are represented with arrows that connect upstream and
downstream factors. Sometimes these sequences are represented in a strictly linear fashion,
sometimes they are cyclical,16 other times they branch with many earlier states leading to
the same final state, or one earlier state leading to many final states. These features of
the pathway concept are common to its other uses in biology. In biochemistry, metabolic
pathways refer to sequential changes in metabolites as they are modified, in biochemical
genetics, gene expression pathways involve step-wise molecular changes that transmit various
signals, and in embryology, developmental pathways characterize the set of changes that an
organism undergoes overtime. In all of these cases, the ordered sequence is significant in the
sense that getting from an earlier state on the pathway to a later state necessitates moving
though the steps or intermediates that span these states. In other words, the only way to get
from an earlier state X to a later state Y, is by progressing through the intermediates that
link these states, unless there is an alternative pathway or route in between these states.
While the sequential or step-wise nature of changes is one important feature of the
pathway model, a second important feature involves that actual states, traits, or phenotypes
that are changing and how they are represented. In the case of stem cell biology, the
steps along the pathway connect up particular stem cell types–types that all derived from
the original multipotent stem cell. These stem cell types are distinguished on the basis of
exhibiting different cell surface and intracellular proteins, structural features, and functional
roles (Kiel, Yilmaz, Iwashita, Yilmaz, Terhorst, and Morrison, 2005). For example, consider
16An example of a cyclical pathway is the Kreb’s cycle a metabolic pathway involved in energy breakdown
and production (Bechtel and Abrahamsen, 2005; Bogen and Machamer, 2010; Bechtel, 2011).
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platelets and erythrocytes, which are downstream products of early multipotent stem cells.
Platelets are colorless cell fragments involved in blood clotting, while erythrocytes are red
disc-shaped cells that primarily serve in oxygen transportation. The different cell receptors
that are used to distinguish stem cell types are referred to as “phenotypic markers” (Wognum
and Szilvassy, 2015). Other downstream products of the early multipotent stem cell also
vary significantly with many playing different roles in immune system functions. So each
step along the pathway represents a particular cell type and the types are lined-up on the
basis of which come before and after others in the developmental process.
A third feature of the pathway model is that for each step in the pathway, particular
factors are viewed as causing or controlling each step. For example, consider one of the first
steps from the original hematopoietic stem cell (HSC) to the common myeloid progenitor
(CMP) cell, on the upper left of the diagram 1. At this step two factors are listed along
the arrow that connects the HSC to the CMP–these two connecting factors are stem cell
factor (SCF) and the hormone thrombopoeitin (Tpo). Scientists claim that SCF and Tpo
“regulate” the proliferation of CMP from HSC and that they are factors that “promote
expansion.”17 In this manner, the factors listed at each step in the pathway model are
viewed as having types of control over the outcome of each step.
I have discussed three main features of the pathway concept as it figures in explanations
of stem cell development. These pathways involve: (1) a sequence of ordered steps, (2) where
some phenomenon or trait is represented at each step, and (3) where these steps are caused
by controlling or regulatory factors. The sparse causal information in the pathway model
raises a number of questions. If developmental processes are complicated and involve, in
some sense, a large number of causally relevant factors, how do these pathway models char-
acterize such processes while containing so few factors and such an economy of information?
Why do scientists represents such few factors as controlling development and what does it
mean to attribute control to these factors? I turn to these questions in the next section by
first introducing the interventionist account and analyzing the pathway model within the
framework of this account.
17For more on this, see: http://www.ebioscience.com/resources/pathways/hematopoiesis-from-
multipotent-stem-cells.htm.
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2.3 CAUSAL REASONING AND THE PATHWAY MODEL.
In this section I provide an analysis of the causal reasoning behind the pathway model. As
my analysis relies on Woodward’s (2003) interventionist account of causation, I first discuss
this account then examine how it can be used to understand the use of pathway models in
explaining stem cell development.
2.3.1 Interventionist account.
Woodward’s interventionist account of causation is motivated by the view that causal re-
lationships are relationships that are potentially exploitable for purposes of manipulation
and control (Woodward, 2003). On this account, the relata of causal relationships are vari-
ables, which represent properties or entities of interest, e.g. genes, phenotypes, etc. These
properties can take on different values, which represent different states of the property in
question. For example, variable C might represent the phenotype “eye color,” where this
variable can take on different values (0, 1, 2,...n), which in this case might refer to different
eye colors (blue, green, brown, etc.). On this account, to say that a variable C is a cause
of variable D means that, given some background circumstances, an ideal intervention that
alters the value of C results in a change in the value of D (Woodward, 2003). To say that
this intervention is “ideal” means that it only alters the value of C, and that this causes a
change in the value of D, through C and not through any other route. The notion of an
ideal intervention is represented in Figure 2 and it is intended to capture the notion of an
unconfounded experimental manipulation of C with respect to D. An ideal intervention on
C with respect to D (i) should not be associated with a variable Y that can cause D, (ii) it
should not directly change the values of D without going through C, and (iii) it should not
directly change the values of any of the intermediate variables that span C to D, without
going through C first.
The causal relationship between these variables can be characterized by a pattern of
counterfactual dependance that captures how specific changes in the value of C would result
in specific values of D. Consider another case where the variable C represents a gene where
9
different values of this variable represent different gene variants {variant 1, variant 2...}.
Additionally, D is a variable representing a trait where this variable can take different values
representing different versions of the trait {trait 1, trait 2...}. To say that C causes D means
that changing C to a specific variant (e.g. variant 1) will cause D to take the value of a specific
trait (e.g. trait 1). For example, suppose that variable C represents the Huntington’s disease
gene and that variable D represents Huntington’s disease. C can take on a range of values
(0, 1, 2, ...) that represent different numbers of trinucleotide repeats in this gene and D
can take on two values (0 or 1), which represent the absence or presence of the disease. To
say that this gene causes Huntington’s disease means that, hypothetically, if there were an
ideal intervention on this gene that changed the number of trinucleotide repeats it contains,
this would control or “make a difference” to whether the patient acquires the disease or not.
Woodward’s account relies on a hypothetical–as opposed to an actual–notion of intervention.
In other words, the intervention need not be one we can actually perform with current
technology, but one that we can hypothetically consider and evaluate. This feature makes
sense of the fact that scientists often cite factors as causes even when they cannot actually
intervene on them. The suggestion is that, when they engage in causal reasoning they
consider the outcomes of hypothetical interventions, or hypothetical changes in the values
of candidate causes with respect to particular effects. This makes sense of the fact that
scientists claim that genes cause various traits and disorders, despite the fact that current
technology is limited in allowing for genetic interventions in humans. The idea is that,
when scientists claim that a gene is the cause of a trait, they mean that if there were some
intervention that changed the gene in particular ways, that this would make a difference
to the manifestation of the trait. Of course, even when scientists cannot actually perform
an experimental manipulation, they may gather other sources of information that provide
evidence of causal relationships.18
18One example of this is a natural experiment, which refers to a situation where natural changes set
up conditions that can be studied as if they were controlled experiments. For example, in the late 19th
century scientists were unable to identify an animal model to use in studying cholera (and they were unable
to experiment on humans due to ethical considerations). At this time scientists used cholera outbreaks in
human populations to study the disease. These outbreaks were a type of natural experiment in the sense
that they involved natural changes or interventions that resulted in disease and that could be used to better
understand disease in humans. In many of these outbreaks the cholera bacilli was identified and, ultimately,
this bacilli was viewed as an important cause of this disease.
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This reveals the importance of hypothetical control in causal reasoning–causes are factors,
such that, if those factors were manipulated they would provide control over the outcome of
interest. On face value, this makes sense given goals in this context–scientists want to identify
factors that control or guide development. Identifying these factors is viewed as providing an
understanding of how this process unfolds in addition to important information about how
to potentially control it, for the purposes of treatment and prevention. For example, to say
that the huntingtin gene is a cause of Huntington’s disease, means that if this gene variant
were manipulated in humans, this would change the occurrence of the disease. In other
words, this gene variant is a kind of light switch for the disease–turning this switch on or off
would change whether the disease was present or absent. Our understanding that this gene
has control over this disease, is partly what explains why efforts at devising treatments focus
on changing this gene variant, or its downstream products. My point here is that assessing
which factors are causes of some outcome involves considering whether these factors, when
manipulated, would provide control over the outcome.
2.3.2 Analysis of the pathway model with interventionist framework.
Recall that the pathway model of stem cell development involves three main features– (1) a
sequence of ordered steps, (2) where some phenomenon or trait is represented at each step,
and (3) where these steps are caused by controlling or regulatory factors. My analysis in
this section will focus on clarifying the reasoning behind these features of the model and the
role they play in explanation.
First, each cell type along the causal pathway can be understood as an outcome or phe-
notype that scientists are interested in explaining. Any particular cell type on the pathway
can be singled out as an effect or outcome to be explained. Furthermore, to provide an expla-
nation, in this context, involves citing the causes of the outcome of interest (where causes are
understood along the lines of the interventionist approach). Consider one of the first steps
on the pathway again, from the HSC to the CMP cell type. In this case, the downstream
CMP cell type represents the explanatory target. The causes that explain this target are the
immediately upstream factors listed on the pathway model–both the original hematopoietic
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stem cell (HSC) and the two controlling factors, SCP and Tpo (which are listed along the
arrow). What does it mean to say that these are the causes of the CMP cell? It means
that each of these factors is a kind of “switch” that, when manipulated, provides control
over whether the CMP cell is produced, or not. The original HSC cell can be represented
as the variable X1, which can take on one of two values (0,1), which represent the absence
or presence of this cell. In order for the CMP cell to be produced, the HSC cell needs to be
present, which is represented by X1 taking on the value (1). If the HSC cell were absent, no
downstream CMP cells could be produced. So manipulating X1 such that it takes on either
value provides control over whether the downstream cell is produced–in the sense that the
presence and absence of the HSC cell makes a difference to whether the CMP cell outcome
occurs.
Of course, just the presence of the HSC cell is not enough to reliably produce the down-
stream CMP cell: there are other factors that interact with this cause to increase the like-
lihood that the downstream cell is produced. Furthermore, most criticisms of the stem cell
model are unlikely to take issue with the claim that an upstream stem cell is, in some way,
causally relevant to production of a downstream cell. What is usually at issue–at least with
respect to the criticisms I focus on–is that there are too few causal factors represented and
that these factors are viewed as “causing” or as having “control” over the developmental
trajectory, where no factors could possibly have such control. These criticisms are motivated
by the view that there are surely numerous causally relevant factors for development, where
no small set of factors can be accurately characterized as “controlling” the developmental
process. Back to our example at hand, in addition to the upstream stem cell, pathway dia-
grams list two other causally relevant factors for the development of CMP from HSC. Why
have scientists listed these factors as controlling this developmental step? What do they
mean by viewing them as causes and why have they not listed other causal factors?
Suppose the original stem cell (HSC) is present, in a living organism or in vitro. When
scientists claim that SCP and Tpo cause HSC to develop into CMP they mean that they
are causes in an interventionist sense–they mean that changes in SCP and Tpo “make a
difference to” whether the CMP cell type develops. More specifically, consider an ideal
intervention that changed the value of SCP: changing whether SCP is present or absent in
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the current environment. Under such an intervention, when SCP is present this increases the
likelihood that the HSC cell will develop into CMP. It doesn’t make the outcome of CMP
development %100 (or even %90) likely, but it makes the CMP outcome much more likely
to occur than it would otherwise be in the absence of SCP. This type of causal relationship
involves what I call probable causal control. This causal control refers to the probability
with which each outcome of the contrastive focus is produced when selected factors are
manipulated. Consider a light switch C, which can take the values ‘up’ or ‘down’ and a light
E, which can take the values “on” or “off.” In the first case, turning the switch “up” results
in a 99% probability of the light bulb being “on” and turning the switch “down” results in a
99% probability of the light bulb being “off.” In a second scenario, turning the switch “up”
has only a 60% probability of causing the light to turn “on” and turning the light switch
“down” only has a 60% probability of turning the light “off.” In both cases the switches
have some causal control over the state of the light, but their control differs with regard to
how probable each outcome of the contrast is with interventions on the switch.19
When scientists identify and search for causes of stem cell development, they might prefer
causes that have a high degree of probable control, but they are often still willing to view a
factor as a cause if it has a lower degree of probable control. In an effort to understand and
identify factors that influence developmental outcomes, scientists are willing to include any
factor with even a small amount of causal control. One problem with common criticisms
of the pathway model of stem cell development, is the following. When a scientists cites
a cause of stem cell development, these criticisms interpret this as a claim that the causal
factor has a high degree of probable control–that this factor provides complete control over
the stem cell outcome in the way that we have complete control over driving a car along a
highway (Robert et al., 2006). This is not the right way to interpret scientist’s claims in
this context: they are not suggesting that these factors have complete or highly probable
control over development, but just that they have at least some control in the sense of a low
degree of probable control over the outcome. It makes sense that they value factors with a
low degree of probable control, in comparison to how they regard factors without control at
19This notion of probable causal control shares similarities with the suggestion by Lu et al. that we look
for causes with high “power” (Lu, Yuille, Liljeholm, Cheng, and Holyoak, 2008).
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all, because these are factors that would allow for control over the outcome if manipulated.
What about all of the other seemingly causally relevant factors that are not represented
in the pathway model? Surely there are many other factors with probable causal control over
the outcome–factors like oxygen, nutrients, and other sustaining constituents. Why are these
left out of the simplified pathway diagram? Again, the interventionist account of causation
clarifies why scientists do not cite these factors as causes. Many of these factors do not meet a
minimal interventionist standard because they do not “make a difference” to the explanatory
target that scientists are interested in. In explanations of stem cell development, scientists
want to explain a particular contrastive focus, which includes the presence or absence of a
downstream stem cell. In the case under discussion, the effect variable Y is the CMP cell,
where this variable takes on two particular values of interest–presence (1) or absence (0) of
the CMP cell. I have already suggested three factors that meet this minimal interventionist
standard: the precursor HSC cell, SCF and Tpo. Aren’t there many factors that make a
difference to this contrastive focus? Consider factors like oxygen, nutrients, other factors
required for life in various organisms. Why aren’t these factors cited or represented in the
pathway diagram? These are factors that don’t “make a difference” to which outcome of
the contrast is obtained, because they are required for both outcomes. These factors are
necessary to consider developmental processes–they don’t take place in humans without
oxygen for example–but they are not factors that control whether various steps unfold or
not.
If we consider a hypothetical intervention of these factors, they make a difference to
whether an organism lives or dies–if they are manipulated (and set to various levels) they
can either kill an organism or sustain life. Scientists do not cite these factors as causes of
stem cell development, because they don’t provide control over the developmental steps they
are focused on. The contrastive focus of interest is whether a downstream cell is produced
or not in a living organism. Thus, given this contrastive focus, scientists assume a situation
where factors required for life are present. They want to know what causes and controls
development in living organisms. Many necessary factors, like oxygen and nutrients, do not
provide this control, although it is the case that they are “causally relevant” in the sense
that they must be present to consider developmental processes in the first place. Thus,
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by specifying a narrow explanatory target, i.e., one that takes place in a living organism,
and by focusing on causes that provide particular types of control, as understood within
the interventionist framework, scientists justifiably exclude from their explanatory model
many factors that one might think of as causally relevant. As it turns out, their selective
process of identifying causes is valuable and reasonable, because it identifies factors that, if
manipulated, would provide control over the progression of stem cell development.
Although scientists are only citing a few factors at each of these steps, this does not
mean that they think that these are the only causally relevant factors at each step. In many
cases, they are still searching for additional causal factors and when they are found, the
pathway model will be updated. In this manner, the pathway diagram isn’t intended as a
comprehensive or final account of development, but as one that captures what is currently
known about the factors that control development.
2.4 CONCLUSION
This chapter provides an analysis of the pathway model as it is used in explanations of stem
cell development. I have suggested that this model has three main features, which include
(1) a sequence of ordered steps, (2) where some phenomenon or trait is represented at each
step, and (3) where these steps are caused by controlling or regulatory factors. Scientists’
identification of these factors as causes can be well-understood with the interventionist ac-
count of causation. More specifically, these are factors that would change or produce an
outcome if they were manipulated in a particular way. The factors represented as causes
in the pathway model are not meant to be exhaustive; they are not viewed by scientists as
the complete set of causal factors that fully explain this developmental process. However,
they are viewed as some of the most important factors that science has thus far identified,
because of the fact that they provide a kind of probable control over the explanatory targets
that scientists focus on. As research continues to reveals other causes of stem cell develop-
ment, scientists will likely revise and update the pathway model. It will be interesting and




Figure 1: Pathway diagram representing differentiation of hematopoeitic stem cells:
http://www.ebioscience.com/resources/pathways/hematopoiesis-from-multipotent-stem-cells.html
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Figure 2: Interventionist account causation (Woodward 2003): notion of an ideal intervention
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3.0 PATHWAY MODEL: SCOPE AND LIMITS
In the last chapter I explored the reasoning and rationale behind the pathway model of
stem cell development, in particular, the use of this model for hematopoietic stem cells.
The current chapter focuses on how this model should figure in various types of decision-
making and how we should best understand its limits and scope. A main focus of this
analysis addresses recent criticisms in the bioethics and philosophy of science literature,
which claim that the oversimplified pathway model badly informs medical decision making
and that those who endorse this model are “behaving unethically” because they rely on a
model that supports the development of stem cell therapies that are unlikely to come to
fruition (Robert et al., 2006, 23). I build on my analysis in the previous chapter to provide
a positive account of when the pathway model can well inform decision-making and when it
over steps reasonable limits.
3.1 PRELIMINARY CONSIDERATIONS
In many ways, it is unsurprising that the discovery of stem cells and their potential has
created so much excitement, particularly with respect to novel disease treatments. The
ability to restore and grow specific types of healthy cells, tissues, and organs would be an
incredible feat that could potentially allow for curative treatments of numerous devastating
and deadly diseases (Kamenova and Caulfield, 2015). Healthy cells might be introduced
into patients with neurodegenerative disorders, like Parkinson’s or Alzheimer’s (Lindvall
and Kokaia, 2006); various types of cancers, like leukemia and lymphoma; or blunt force
injuries that destroy functioning of vital cells, tissues, or organs. The ability to create
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cellular products from precursor stem cells of individual patients would have the potential
to provide a specific treatments, with a higher likelihood of being accepted by the patient’s
immune system without deleterious consequences. These potential treatments contrast with
common donor transplantations procedures where patients receive donor products–like blood
transfusion and organ donation–and incur a risk of product rejection, host-graft reactions,
and immune suppression side effects. Such donor procedures involve onerous challenges for
developing successful treatments, in part, because of the complications associated with the
acceptance and growth of foreign donor products in patients. Amid longstanding challenges
in modern medicine and an awareness of common, plaguing ailments, stem cells can provide
an intriguing and irresistible hope. This hope has surely influenced their representation in the
media and scientific contexts, which often engage in hyperbolic discussion and expectations.
Stem cells have been touted as a providing technology that will “revolutionize the future” of
medicine and provide “panaceas for every imaginable disease” (Bongso and Richards, 2004,
827, 828). While most statements on the potential for stem cell treatments have not been
this optimistic (or exaggerated), most early and current views on stem cell research have
been highly positive.1
However, while stem cell research has contributed to medical understanding and (as I
will discuss shortly) particular medical treatments, it has yet to supply the groundbreaking
advancements that many hoped it would deliver. These perceived shortcomings have con-
tributed to the view that medical researchers have misrepresented the nature of stem cell
development and their ability to harness this development for medical use. In the wake of
these claims, the pathway model of stem cell development has become a target for criticisms.
Robert et al (2006) claim that this model is “misleading” in because promotes a picture of
development that is more simplified, controllable, and fixed that it actually is (Robert et al.,
2006). These authors have associated such a fixed view with a “mechanistic” framework–or
orientation to biological topics–that encourages dividing up biological systems into discrete
parts, which interact in predictable ways to produce some outcome of interest.2 Robert et
1For example, see: (Segers and Lee, 2008; Baksh, Song, and Tuan, 2004; Reya, Morrison, Clarke, and
Weissman, 2001).
2This mechanistic paradigm is alive and well in the philosophy of science literature, particularly in the
areas of biology and neuroscience. This current mechanistic framework is often viewed as having originated
from a seminal paper by (Machamer, Darden, and Craver, 2000), which has received significant attention
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al (2006) have associated the fixed, decomposable nature of the mechanistic framework with
the tendency to view stem cell development as controllable, and divisible into discrete causal
components. Instead, they support a view of development as a dynamic and holistic process
that is not easily divisible into causes or component parts. To support such a mechanistic
view in this context, is to suggest unlikely future stem cell therapies. These authors use
this line of criticism to claim that scientists who use the pathway model are acting “un-
ethically,” because they purposefully misrepresent the current state of this research and its
future potential. Robert et al (2006) state:
Those scientists who publicly endorse a simplistic mechanistic metaphor (often by sim-
plifying their own scientific understanding of the complexities of the biological system)
are behaving unethically, because this particular way of simplifying the science suggests
promises for therapeutic applications that we know to be extremely improbable. (Robert
et al., 2006, 23, emphasis added)
Are scientists who endorse this model acting unethically? How should the pathway model
of stem cell development influence decision-making about research funding, if at all? Does
this model suggest treatments that we know will not come to fruition or, alternatively, does
it suggest treatments that we have good reason to expect and pursue through scientific re-
search? Addressing these questions matters for a number of reasons. First, the resources
we have for scientific research are limited; we want to make sure that they are directed
towards projects that can better medical practice and patient lives. Furthermore, the ways
that scientists communicate current scientific research influences patients, patient’s families,
and societal understanding of ailments and expectations for medical care. If these popu-
lations expect newly emerging medical treatments because scientists suggest that they are
around the corner, the lack of such developments could lead to a mistrust of the biomedical
community. Finally, misleading communication of scientific research can place patients and
others at risk if such practices encourage clinical trials that are not based on sound research
and involve unknown or unappreciated harms. Being able to clarify how the pathway model
in philosophy of science. For example, dominant views in these fields maintain that most or all of the
explanations in biology and neuroscience are mechanistic (Kaplan and Craver, 2011; Craver, 2007, 2006) and
that “the concept of a mechanisms generates the clearest picture of molecular biology’s history, concepts, and
case studies utilized by philosophers of science” (Tabery, Darden, and Piotrowska, 2015). The mechanistic
paradigm has become the mainstream account of explanation and understanding in philosophy of biology
and neuroscience.
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of stem cell development should inform medical decision-making and allocation of research
funding are non-trivial topics that deserve further attention.
The rest of my analysis in this paper focuses on the following questions: What con-
clusions or decisions can current scientific understanding of stem cells support? How does
understanding of the causal reasoning involved in the pathway model translate into assess-
ments of likely (or unlikely) future therapies? This chapter focuses on three main features
that clarify constraints on decision-making that is influenced by or reliant on the pathway
model. These constraints include (1) the type of stem cells under consideration, (2) the
surrounding environment of the stem cells, and the (3) form of stem cell treatment being
discussed.
3.2 THE PATHWAY MODEL: LIMITS AND SCOPE
As suggested in the previous chapter, scientists use the pathway model of stem cell develop-
ment to identify and discuss factors that cause or provide causal control over developmental
outcomes. Robert et al (2006) are correct in claiming that scientists select factors as con-
trolling development. However, I view this selection of factors with causal control as backed
by a principled rationale. Scientists select factors as causes when these factors, after being
manipulated, would provide control over the outcome of interest.3 In this section I consider
what more can be said about how this reasoning should bear on assessments of the future
therapeutic potential of stem cells.
First, what, if anything, gives us reason to think that the pathway model of stem cell
development is accurately predictive of the future development of therapies? One reason
to view the pathway model as a reliable indicator of the potential for future treatment, is
that the causal factors it identifies are currently used in treatments that provide control
over therapeutic outcomes. In other words, some of the causal factors that scientists local-
ize on the pathway model of hematopoietic stem cell development are already targeted to
successfully control cellular development. Consider the pathway diagram again (Figure 1),
3For more on this see chapter 2.
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from chapter 2. On the left-hand side, near the middle lower portion of the diagram there
is a causal link between an erythrocyte progenitor cell and an erythrocyte (or red blood
cell). The factor that links the upstream progenitor cell and the downstream erythrocyte
is erythropoietin (EPO), a glycoprotein hormone that stimulates red blood cell production.
EPO is routinely administered to patients to stimulate production of red blood cells. This
treatment is provided to patients with anemia or certain forms of cancer that diminish red
blood cell levels. In addition to this, EPO has been used as a performance enhancing drug
in many sports, as increased red blood cell count confers a cardiovascular advantage (Juul
and Felderhoff-Mueser, 2007; Lodewijkx and Brouwer, 2011). Scientists state that EPO
“controls the production of erythrocytes in mammals,” which is a causal claim that is well-
interpreted with the interventionist account. Specifically, intervening on and changing levels
of EPO results in changes in levels of red blood cell production (Koury and Bondurant, 1992,
649). The fact that some causal factors on the pathway model are related to actual, suc-
cessful treatments indicates that it is incorrect to view this model as suggesting therapeutic
promises that we know to be unlikely, as Robert et al (2006) claim. EPO supplementation is
not the only medical therapy that demonstrates the principles of the pathway model of stem
cell development. Another example of a successful stem cell therapy is transplantation of
hematopoietic stem cells. I discuss this treatment modality more in subsection 3.2.3., where
I consider various forms of stem cell therapies. My point here is simply that, before consid-
ering the limitations of the pathway model, it is important to note that we have evidence
that the pathway model accurately depicts causal reasoning based on experimental findings.
3.2.1 Stem cell type
Part of understanding how the pathway model should influence decision-making about the
allocation of research resources requires clarifying the scope and limits of the claims it can
support. In particular, assessing the likelihood of future stem cell therapies depends on the
(1) particular type of stem cell, (2) environment of stem cell development, and (3) form of
therapy. My analysis of the pathway model has focused on hematopoietic stem cell research–
the most extensively studied and understood stem cell type. In considering assessments of
23
stem cell therapies, our scientific understanding of hematopoietic stem cells should be viewed
as most directly relevant to assessing the potential of therapies with hematopoietic cells, as
opposed to other stem cell types. Just because current experimentation has identified factors
that control hematopoietic stem cell development, does not indicate that such factors will
also be found for other stem cells, for example, stem cells in neural, cardiac, or hepatic
tissues. This point might seem obvious or trivial, but it is easy (and exciting) to consider
the many diseases that might have treatments if all stem cell types had features we know
to be common to hematopoietic cells. The ability to regenerate patient specific tissues,
organs, and cell types is a very intriguing treatment modality, which is easy to relate to
various conditions that are devastating, fatal, or currently lack treatments.4 However, current
understanding of features of hematopoietic stem cell development does not yet provide clear-
cut information about other stem cells. If claims about future therapies with other cells are
made by drawing on hematopoietic research, some rationale or justification for the connection
should be provided. Otherwise, extending claims that are accurate about hematopoietic stem
cells to non-hematopoietic cells is one way in which the pathway model can be extended
beyond its limits to provide conclusions that are unwarranted.
3.2.2 Stem cell environment
A second constraint of the pathway model is that it depends on a particular environment
or set of background conditions, which is not always made explicit. Experimentation with
hematopoietic stem cells involves setting up environments where many external conditions
are held fixed or controlled in various ways, while the value of some candidate cause is varied
to test for its relationship to an experimental outcome. For example, factors like temperature,
availability of nutrients, and even genetic make-up of an animal model can be set fixed at
particular values. An advantage of controlling factors in this way is that it can provide
reliable evidence for causal relationships. If multiple factors or variables are changing within
4If it were possible to create patient specific hepatic, cardiac, or neural cells, for example, we might have
the ability to combat diseases that are common or have few successful treatments. The possibility to provide
healthy patient-specific cells for diseases that irreversibly damage tissues and organs–like brain cancer or
sever liver failure–is difficult to ignore given how hard it is to successful cure and alleviate suffering for
patients with such conditions.
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an experiment, it can be difficult to assess which of these variables is causally relevant to an
outcome. For example, if we wanted to test whether EPO is causally relevant to increased
red blood cell production, we could vary EPO levels in mouse models, where EPO levels
are the only difference across the models. If we vary EPO levels in these mouse models, in
the sense of an ideal intervention discussed in chapter 2, and we see differences in red blood
cell production, we have good evidence that this change is due to EPO levels as opposed to
some other candidate cause. This is because the mice either do not have differences across
other identifiable candidate causes, or if they do, the intervention is such, that it is not
correlated with changes in these factors. However, the ways in which we control factors in
experimentation often differs from how we control factors in human patients, which is the
population to which we are often interested in extended experimental claims. Even though
experimentation with animal models indicates that EPO has causal control over red blood
cell production in mice, it may be the case that there are other causal variables that also
influence red blood cell production, but that we have not identified yet, perhaps because
we have (unknowingly) held them constant in the experimental set up or failed to measure
them altogether.5
Identifying and studying a causal factor in such an experiment, is relative to an envi-
ronment where many other potential candidate causes are held fixed. We may not be able
to hold these external causal factors fixed in other situations–e.g. in other animal models,
experimental settings, or even in human patients, where we ultimately aim to develop treat-
ments. In this manner, the pathway model of stem cell development–and the causal factors
it identifies–are dependent on assumptions about holding various external factors constant.
5Recent work on hematopoietic stem cells suggests that there many more factors with roles in controlling
development than scientists previously thought. Scientists are starting to refer to stem cell “niches” as sets
of causal factors that make up micro-environments, which influence development(Li and Li, 2006). These
niches are related to both bone and vascular areas, and are thought to involve various signaling factors that
regulate development (Chotinantakul and Leeanansaksiri, 2012; Zhang, Niu, Ye, Huang, He, Tong, Ross,
Haug, Johnson, Feng, Harris, Wiedemann, Mishina, and Li, 2003). Experimental work with stem cell niches
is relatively new, and these complex micro-environments are much more difficult to control and measure than
other single factors like EPO. Thus, although it may be the case that such a niche concept well-characterizes
some features of stem cell development, current developmental understanding and the pathway model do not
assume such a context or environment. To export causal claims made with the pathway model to stem cell
development in other environments (like a complex microenvironment of causal factors or niche) is currently
premature, and scientists are often qualifying their causal claims about stem cells to particular environments,
within which these causal relationships are studied and supported by research.
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To say that EPO is a cause of red blood cell production, means that when EPO is
manipulated with an ideal intervention, in a context where other factors are held constant,
that this results in a change in red blood cell production. If scientists attempt to export
this causal claim to situations where these assumptions do not hold, further justification for
the claim should be provided. This point clarifies another way in which the pathway model
can be extended beyond its limits. The causal reasoning of the pathway model is guided by
experimental work, which relies on various assumptions, including the assumptions about
simplified experimental situations. Thus, the conclusions about future stem cell therapies
that are drawn from the pathway model are importantly dependent on assumptions inherent
to the experimental work on which the model relies. This relativity of causal claim to a
set of background conditions is standard for causal claims made in scientific fields. For
example, when a scientist claims that saturated fat causes heart disease, she does not mean
that saturated fat is the only cause of this disease or that it causes this disease in every
person, no matter what other extenuating circumstances are present. There are many other
extenuating circumstances that can significantly change whether a person gets this disease
while eating a high diet in saturated fat. For patients who eat a high diet in saturated fat,
some factors can make acquiring heart disease more likely (e.g., lack of exercise, increased
sugar consumption, etc.) and other factors can make the likelihood of this disease much
lower (e.g., sufficient exercise, antioxidants, other medications, etc.). When scientists make
this causal claim, they usually assume a particular set of background conditions, where
other causal factors are held fixed in some range of values, so as to not influence the causal
relationship in question. Of course, scientists are not claiming that saturated fat is the only
cause of heart disease, or that other factors don’t influence this relationships, but just that
in a particular standard background context the causal variable provides causal control over
the effect variable, in the interventionist sense discussed in chapter 2.
3.2.3 Stem cell therapy
A final consideration that clarifies how the pathway model should be used to support claims
about stem cells, involves the type of stem cell therapy that is considered. Different forms of
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stem cell treatments can vary in difficulty of implementation, relation to current understand-
ing in stem cell biology, and relative likelihood of success given current scientific knowledge.
While the pathway model identifies a variety of causal factors and causal relationships that
characterize development, there are different ways that these factors can be exploited in
medical treatments. One example of a particular stem cell treatment, is hematopoietic stem
cell transplantation, which is a treatment currently in use in biomedicine where multipo-
tent hematopoietic stem cells are transplanted into a patient. This treatment is used in
patient’s with cancers like multiple myeloma or leukemia,6 where cells in the blood or bone
marrow are defective. In these patients, the defective store of immune cells are destroyed
with irradiation and healthy hematopoietic cells are introduced via transplantation.7 This
procedure relies on the ability of the healthy precursor hematopoietic stem cells to develop
into all necessary downstream cells. This treatment involves a fairly low degree of technical
control, as healthy precursor cells are introduced and left to develop in the patient’s body
without any further guidance or manipulation on the part of the researchers or therapy. The
patient’s body dictates downstream development of the precursor cell. In this treatment,
our understanding of the step-wise development of hematopoietic cells and the factors that
play a role in guiding this development does not translate into a focused target of controlling
factors or treatments that single out the causes of development. Instead, the model captures
the step-wise process of differentiation that transplanted cells follow: the model is entirely
compatible and suggestive of this stem cell therapy, which has been successfully used to treat
patients with these disorders. Commentators like Robert (2006) et al. should not claim that
the pathway model of stem cell development inappropriately suggests the likelihood of suc-
cessful transplantation therapies, because such therapies are already in use and successful
in treating various diseases. However, not all of these therapies rely on using the identified
causal factors in the pathway models as targets that we might exploit in treatment. Instead,
healthy stem cells are introduced into a patient and the normal factors present in the patient
6Additional disorders that involve this treatment include acute myloid leukemia, chronic myeloid leukemia,
acute lymphoblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, Neuroblastoma, Ewing sar-
coma, Multiple myeloma, Myelodysplastic syndromes, glioma, thalassemia, sickle cell anemia, aplastic ane-
mia, immune deficiency syndromes, and inborn errors of metabolism.
7These can be stem cells harvested from the patients that are treated (e.g, autologous transplantion) or
they can be mixed stem cells, which are derived from both the patient and a donor (allogeneic transplantion)
(Schuster, Stupnikov, Ma, Lai, Ma, and Aguila, 2012).
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guides development of the cells.
Part of what this example shows, is that there are many ways in which stem cells can
figure in treatments, and determining how the pathway model figures in discussions of future
therapies depends on what particular therapies are under for consideration. To say that
this model supports confidence in developing one medical treatment (like transplantation
or EPO-based therapies) is not to say that it can or should be used to support confidence
in any imaginable type of treatment. For example, this model is less likely to support
confidence in treatments that require highly fine-grained control over stem cell differentiation,
because the pathway model does not identify factors with such control. To use this model
to support claims of the imminent future development of stem cell treatments with fine-
grained control, is to use this model inappropriately. If a scientist makes this claim without
providing any kind of further rationale beyond the model itself, this might raise concerns
about the motivation behind such claims and what negative consequences they may have,
if taken seriously. What kinds of further rationale might be provided here? In many cases,
the best kind of evidence is experimental work that reveals a type of control or therapeutic
outcome that a future treatment would involve. Experiments which demonstrate the ability
to control developmental outcomes with therapeutic measures, in particular, with animal
models, would provided some of the best reassurance of likely future therapies in humans.
In discussing the potential for future neural stem cell therapies, Lindvall and Kokaia (2006)
state:
It would be premature to launch clinical trials to use stem cells to treat neurological disor-
ders. However, steady progress supports the hope that stem-cell-based therapies to restore
and preserve function in the brain and spinal cord can be developed...Before we apply stem-
cell therapies to patients, we must be able to control the proliferation and differentiation of
stem cells into specific cellular phenotypes and to prevent tumour formation. Furthermore,
the efficacy of stem cells and their mechanisms of action should be demonstrated in ani-
mal models with pathology and symptomatology resembling the human disease.... Finally,
we must remember that however exciting the neurobiological mechanisms might be, the
clinical usefulness of stem cells will be determined by their ability to provide patients with
neurological disorders with safe, long-lasting and substantial improvements in quality of
life. (Lindvall and Kokaia, 2006, 1096)
This statement reveals a number of helpful points. First, it indicates that many scientists
who are interested in identifying stem cell therapies (in areas beyond just the hematopoi-
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etic system) stress the importance of experimental evidence before viewing such therapies
as attainable or appropriate for clinical trial testing. Gaining evidence of successful control
in animal models is an important step in achieving stem cell therapies. Second, this state-
ment reveals the care with which scientists can take claims about particular stem cells–in
these case neural stem cells and their ability to treat various neurodegenerative disorders.
Although hematopoietic treatments are available and used, some scientists are careful not
to immediately export these results to neural stem cells, without appropriate rationale. Fi-
nally, as suggested at the end of the quotation, the aim of developing stem cell treatments
is not just to display control over a complex developmental process, but to afford patients
long-term enhancements in their quality of life.
There are many different ways in which we can conceive of using stem cells in novel
treatments of human disease. Some of these treatments will be more difficult to carry out
than others, some will be more straightforwardly achievable, and others will be more similar
to experimental work that is already underway (and successfully used to counteract disease in
animal models). Whether the pathway model supports the likelihood of developing successful
therapies depends on exactly what therapies are considered. To make the general claim that
this model fundamentally suggests treatments that we know to be unattainable is clearly
incorrect–successful stem cell therapies are already in use and their method of functioning is
clarified by the pathway model. However, it is clear that this model alone cannot reasonably
indicate the likelihood of developing just any kind of future stem cell therapy–the particular
therapies it most straightforwardly suggests involve those that target the causal factors it
identifies or that rely on step-wise formation of cells after transplantation of precursor cells.
3.3 BIOETHICAL CONSIDERATIONS
What claims about stem cell therapies would it be unethical for scientists to make, when
drawing on the pathway model of stem cell development? What makes them unethical? I
have suggested that scientist’s claims should be importantly constrained by (1) stem cell
type, (2) stem cell environment, and (3) stem cell treatment. When claims about potential
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stem cell therapies are not constrained by these features, further rationale should be provided
and claims should be more carefully examined. In this section I further examine why these
claims are unethical and what can motivate or pressure scientists into making them.
One clear reason that scientists may exaggerate the promise of future stem cell therapies,
is that their own research may benefit from such claims. The ability to secure research
grants, other sources of funding, and attention in social and scientific settings is often aided
by the perceived potential for a research program to translate into life-saving or enhancing
care. Such perceptions of life-saving potential often allow research programs and labs to be
much more competitive in securing funding and other resources8 and justifying the continued
value of their research. In a university and private sector climate where scientists are under
pressure to secure grants, it is easy to understand their motivation to err on overselling the
potential therapeutic outcomes of their work, even if such therapeutic outcomes are still
more of a pipe dream. Gannet (1999) discusses scientists tendency to do this as being driven
by their “professional interest” and the fact that they have a“professional stake” in the
matter (Gannet, 1999, 359). The inability to gain funding or attention can jeopardize their
own career and job security, and can encourage them to inaccurately characterize their own
work. Such mischaracterization of scientific research is often considered a form of scientific
misconduct. As Macrina states:
“[scientists] can fall prey to self-deception, rationalizing their actions in ways that mislead
themselves and others. The term “sloppy science” is frequently used to describe some
behaviors, but the distinction between sloppy science and scientific misconduct can be
nebulous. Those seeking clear-cut answers commonly invoke the idea of deliberate deception
as the defining element in misconduct.” (Macrina, 2005, 2)
These misrepresentations of scientific work are not just problematic because of the false
nature of the information or the intent of scientists to purposefully mislead others. These
misrepresentations can have significant consequences that (1) place patients in harms way, (2)
waste limited resources for medical research, and (3) degrade trust in the medical community,
by giving patients, patients’ families, and society false hopes for therapeutic breakthroughs.
Exaggerating the potential for stem cell therapy breakthroughs could encourage clinical trials
and steps towards clinical use of a research modality before there is sufficient reason to do
8For example, resources like lab space at a university, graduate students, faculty, and assistants.
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so. One worry is that this rushed treatment implementation in patients, exposes them to
increased risks as the treatment has not been adequately evaluated.
In addition to potentially placing patients at risk, exaggerated claims about the potential
for stem cell therapies can funnel limited resources away from research that may positively
benefit patients. Even if stem cell research was not rushed into clinical trials on the basis
of exaggerated claims, it could stagnate on its way to this step while nevertheless draw-
ing resources away from other projects that could have resulted in successful therapies or
scientific breakthroughs. The scarcity of resources and immense advantage that successful
treatments can afford patients, make issuing inaccurately positive claims about stem cell
therapies unethical. Such claims increase the likelihood of wasting precious resources that, if
employed differently, could significantly better patient lives. Finally, if scientists continually
make promises about future treatments that fail to pan out, the broader public may lose
trust in their claims and in biomedicine in general. This might result in reduced funding
of scientific research, increased questioning of physicians and medical researchers in clinical,
research and other settings, and a degrading of the relationship between science researchers
and the broader public. Of course, there is always an element of uncertainty when scientists
make predictions about future treatments. We should want scientists to strive for treatments
and even be creative and hopeful in their aims to achieve new treatment goals. Nevertheless,
the predictions they provide should be carefully grounded in current research, experimental
evidence, and scientific understanding. The three topics discussed in this chapter–(1) stem
cell type, (2) stem cell environment, and (3) type of stem cell therapy–provide dimensions
along which their predictive claims should be assessed.
One important theme that this analysis raises is how scientists communicate their re-
search to others, e.g. their peers, patients, and the broader public. Instead of just assuming
that there are issues with the pathway model, it should be carefully studied and understood.
In particular, the pathway model should be viewed as a helpful and important medium for
communicating scientific ideas to various audiences. Research has shown that illustrations
and diagrams are helpful tools for conveying complex scientific information (Maddalena,
2013). This suggests a helpful role for the pathway model in communicating causal infor-
mation about developmental processes. As has been discussed in this project, this model
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involves important assumptions that must be clarified to understand the information it
conveys. Relying on this model to communicate information requires appreciating and ac-
knowledging these assumptions, in addition to the limits and scope of the model. Further
work on the reasoning and limits of pathway models of stem cell development would be
welcome as stem cell research continues to develop and gain attention.
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4.0 CONCLUSION
Causal complexity appears to be ubiquitous in biology. For many biological phenomena,
there are numerous causally relevant factors. This multiplicity poses an interesting chal-
lenge for efforts to explain and understand biological phenomena. If the causes of biological
outcomes are so numerous, it is difficult to see how we could possible cite them all, or com-
municate such information to our peers or society at large. Depending on their goals and
interests, scientists often find ways of prioritizing some causal factors over others and ab-
stracting from significant amounts of causal detail in the explanations they provide. The
factors that scientists choose to privilege in their explanations of scientific phenomena mat-
ter. The factors they privilege can receive more attention in research, clinical, and social
settings, and can be viewed as targets for developing medical treatments. If biological phe-
nomena are extremely causally complex, then scientists will often need to prioritize some
causes over others in their explanations. Future work in bioethics and philosophy of science
should work to better understand how scientists reason in these situations, whether and
how such reasoning practices are justified, and the ethical implications of their reasoning
practices, and whether such practices.
The pathway model represents a select set of causal factors, which scientists view as
importantly characteristic of stem cell development. The notion of a pathway is common
in biology and it typically involves at least three main features: (1) a sequence of ordered
steps, (2) where some phenomenon or trait is represented at each step, and (3) where these
steps are caused by controlling or regulatory factors. The pathway steps usually represent
some biological state of interest and additional factors are represented as factors that control
the unfolding of these steps. I have suggested that when scientists identify and cite causes
of stem cell development, they are identifying factors that, when manipulated, “make a
33
difference” to the occurrence and non-occurrence of these steps. These are factors that, when
hypothetically manipulated, increase the probability of producing the outcome of interest.
Finally, the pathway model should be viewed as a useful current model, but not one that
is in its final or complete form. As scientists gain more information about the causes of stem
cell development, they will revise and modify this model. As these revisions take place, it
will be important for us to consider why scientists are characterizing development in the
ways that they do, what experimental work underlies their characterizations, and how their
characterization influences our expectations for future medical breakthroughs.
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